FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138863592> ?p ?o ?g. }

• W2138863592 endingPage "506" @default.
• W2138863592 startingPage "7497" @default.
• W2138863592 abstract "The primary study objective was to determine the safety of intraprostatic administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD)/herpes simplex virus thymidine kinase (HSV-1 TK) fusion gene concomitant with increasing durations of 5-fluorocytosine and valganciclovir prodrug therapy and conventional-dose three-dimensional conformal radiation therapy (3D-CRT) in patients with newly diagnosed, intermediate- to high-risk prostate cancer. Secondary objectives were to determine the persistence of therapeutic transgene expression in the prostate and to examine early posttreatment response. Fifteen patients in five cohorts received a single intraprostatic injection of 10(12) viral particles of the replication-competent Ad5-CD/TKrep adenovirus on day 1. Two days later, patients were administered 5-fluorocytosine and valganciclovir prodrug therapy for 1 (cohorts 1-3), 2 (cohort 4), or 3 (cohort 5) weeks along with 70-74 Gy 3D-CRT. Sextant needle biopsy of the prostate was obtained at 2 (cohort 1), 3 (cohort 2), and 4 (cohort 3) weeks for determination of the persistence of transgene expression. There were no dose-limiting toxicities and no significant treatment-related adverse events. Ninety-four percent of the adverse events observed were mild to moderate and self-limiting. Acute urinary and gastrointestinal toxicities were similar to those expected for conventional-dose 3D-CRT. Therapeutic transgene expression was found to persist in the prostate for up to 3 weeks after the adenovirus injection. As expected for patients receiving definitive radiation therapy, all patients experienced significant declines in prostate-specific antigen (PSA). The mean PSA half-life in patients administered more than 1 week of prodrug therapy was significantly shorter than that of patients receiving prodrugs for only 1 week (0.6 versus 2.0 months; P < 0.02) and markedly shorter than that reported previously for patients treated with conventional-dose 3D-CRT alone (2.4 months). With a median follow-up of only 9 months, 5 of 10 (50%) patients not treated with androgen-deprivation therapy achieved a serum PSA < or = 0.5 ng/ml. The results demonstrate that replication-competent adenovirus-mediated double-suicide gene therapy can be combined safely with conventional-dose 3D-CRT in patients with intermediate- to high-risk prostate cancer. The shorter than expected PSA half-life in patients receiving more than 1 week of prodrug therapy may suggest a possible interaction between the oncolytic adenovirus and/or double-suicide gene therapies and radiation therapy." @default.
• W2138863592 created "2016-06-24" @default.
• W2138863592 creator A5013666532 @default.
• W2138863592 creator A5024956326 @default.
• W2138863592 creator A5029752704 @default.
• W2138863592 creator A5037922132 @default.
• W2138863592 creator A5044435425 @default.
• W2138863592 creator A5046625473 @default.
• W2138863592 creator A5047699389 @default.
• W2138863592 creator A5052710017 @default.
• W2138863592 creator A5055379120 @default.
• W2138863592 creator A5082470669 @default.
• W2138863592 creator A5091841617 @default.
• W2138863592 date "2003-11-01" @default.
• W2138863592 modified "2023-10-11" @default.
• W2138863592 title "Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer." @default.
• W2138863592 cites W113406503 @default.
• W2138863592 cites W1516866556 @default.
• W2138863592 cites W1673640638 @default.
• W2138863592 cites W1755993224 @default.
• W2138863592 cites W1808107661 @default.
• W2138863592 cites W1868732334 @default.
• W2138863592 cites W1894827484 @default.
• W2138863592 cites W1943398466 @default.
• W2138863592 cites W1970400785 @default.
• W2138863592 cites W1976578751 @default.
• W2138863592 cites W1979819510 @default.
• W2138863592 cites W1984994876 @default.
• W2138863592 cites W1987484894 @default.
• W2138863592 cites W1990050184 @default.
• W2138863592 cites W1992119768 @default.
• W2138863592 cites W1993657718 @default.
• W2138863592 cites W1996550652 @default.
• W2138863592 cites W1997414785 @default.
• W2138863592 cites W1998100071 @default.
• W2138863592 cites W1998798788 @default.
• W2138863592 cites W2018445655 @default.
• W2138863592 cites W2022266950 @default.
• W2138863592 cites W2023801183 @default.
• W2138863592 cites W2030831603 @default.
• W2138863592 cites W2032554540 @default.
• W2138863592 cites W2037426238 @default.
• W2138863592 cites W2038590203 @default.
• W2138863592 cites W2044700629 @default.
• W2138863592 cites W2046627726 @default.
• W2138863592 cites W2049153532 @default.
• W2138863592 cites W2049670016 @default.
• W2138863592 cites W2053981403 @default.
• W2138863592 cites W2056643793 @default.
• W2138863592 cites W2065184437 @default.
• W2138863592 cites W2072015251 @default.
• W2138863592 cites W2078162122 @default.
• W2138863592 cites W2085834739 @default.
• W2138863592 cites W2089217768 @default.
• W2138863592 cites W2090341996 @default.
• W2138863592 cites W2093485750 @default.
• W2138863592 cites W2096700379 @default.
• W2138863592 cites W2103429819 @default.
• W2138863592 cites W2108293103 @default.
• W2138863592 cites W2108773718 @default.
• W2138863592 cites W2112285253 @default.
• W2138863592 cites W2113534698 @default.
• W2138863592 cites W2122101164 @default.
• W2138863592 cites W2127935661 @default.
• W2138863592 cites W2128917900 @default.
• W2138863592 cites W2130641534 @default.
• W2138863592 cites W2135792629 @default.
• W2138863592 cites W2135913770 @default.
• W2138863592 cites W2137900501 @default.
• W2138863592 cites W2140544523 @default.
• W2138863592 cites W2143994823 @default.
• W2138863592 cites W2144498681 @default.
• W2138863592 cites W2146780512 @default.
• W2138863592 cites W2150927595 @default.
• W2138863592 cites W2153674426 @default.
• W2138863592 cites W2161025906 @default.
• W2138863592 cites W2163120057 @default.
• W2138863592 cites W2165671852 @default.
• W2138863592 cites W2165699027 @default.
• W2138863592 cites W2171210159 @default.
• W2138863592 cites W2222589758 @default.
• W2138863592 cites W2297484127 @default.
• W2138863592 cites W2408947935 @default.
• W2138863592 cites W2410650233 @default.
• W2138863592 cites W2414495570 @default.
• W2138863592 cites W2465489203 @default.
• W2138863592 cites W2472051258 @default.
• W2138863592 cites W2774384288 @default.
• W2138863592 cites W53877061 @default.
• W2138863592 cites W2804759819 @default.
• W2138863592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14612551" @default.
• W2138863592 hasPublicationYear "2003" @default.
• W2138863592 type Work @default.
• W2138863592 sameAs 2138863592 @default.
• W2138863592 citedByCount "94" @default.
• W2138863592 countsByYear W21388635922012 @default.
• W2138863592 countsByYear W21388635922013 @default.
• W2138863592 countsByYear W21388635922014 @default.

• next